US EditionTrump says price of weight-loss drug Ozempic will be lowered in the US
Trump announced plans to cut the price of Novo Nordisk’s weight-loss drug from $1,300 to $150, aiming to reduce U.S. drug costs under the Most Favored Nation policy.
- On Thursday, US President Donald Trump said at a White House event that a drug would be made cheaper, prompting Novo Nordisk shares to fall 5.6% in early trade on Friday.
- With Ozempic commonly used off-label, Novo Nordisk said on Thursday it has engaged in discussions with the Administration about the Most Favoured Nation policy to limit US drug prices.
- Novo Nordisk's shares fell after Trump said, 'I was referring to Ozempic, or- I was referring to- the fat loss drug?.... They'll be much lower,' UBS analysts noted they had already factored US price cuts.
- A Novo Nordisk spokesperson said the company focused on patient access and affordability but did not comment on President Donald Trump's remarks, while Dr. Mehmet Oz said GLP-1 drug negotiations will continue until the president is satisfied.
- With more entrants, including Pfizer and AstraZeneca, the GLP-1 category remains un-negotiated, JPMorgan said lower prices could boost volumes while BMO called the market reaction `overdone` and noted insured individuals pay as low as $25/month.
41 Articles
41 Articles
Fox Business
The New York LedgerTrump says Ozempic prices will be 'much lower' for Americans
Novo Nordisk's blockbuster diabetes and weight loss-related drug Ozempic is set to see a price cut, according to President Donald Trump. Trump said this week during a White House event on fertility treatments and drug pricing that the price reduction will come after swift negotiations with the drugmaker."They'll be much lower," Trump told reporters. TRUMP'S QUEST TO REDUCE DRUG PRICES IS HEATING UP. BUT WILL HE BE ABLE TO DO IT?Novo Nordisk is t…
The Independent
The Independent (US)Weight loss drug shares down after Trump promises Ozempic price cut
The comment from Trump has investors worried about a worst-case scenario for the obesity landscape
Is Trump Going to Kill the GLP-1 Cash Cow?
Key Points GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but President Trump’s vow threatens deeper reductions. Shares are 3% or more this morning as investors brace for profit erosion. Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes …
Coverage Details
Bias Distribution
- 39% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
